Literature DB >> 18992264

Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.

Marcelo Carvalho1, Maria A Pino, Rachel Karchin, Jennifer Beddor, Martha Godinho-Netto, Rafael D Mesquita, Renato S Rodarte, Danielle C Vaz, Viviane A Monteiro, Siranoush Manoukian, Mara Colombo, Carla B Ripamonti, Richard Rosenquist, Graeme Suthers, Ake Borg, Paolo Radice, Scott A Grist, Alvaro N A Monteiro, Blase Billack.   

Abstract

Germline mutations that inactivate BRCA1 are responsible for breast and ovarian cancer susceptibility. One possible outcome of genetic testing for BRCA1 is the finding of a genetic variant of uncertain significance for which there is no information regarding its cancer association. This outcome leads to problems in risk assessment, counseling and preventive care. The purpose of the present study was to functionally evaluate seven unclassified variants of BRCA1 including a genomic deletion that leads to the in-frame loss of exons 16/17 (Delta exons 16/17) in the mRNA, an insertion that leads to a frameshift and an extended carboxy-terminus (5673insC), and five missense variants (K1487R, S1613C, M1652I, Q1826H and V1833M). We analyzed the variants using a functional assay based on the transcription activation property of BRCA1 combined with supervised learning computational models. Functional analysis indicated that variants S1613C, Q1826H, and M1652I are likely to be neutral, whereas variants V1833M, Delta exons 16/17, and 5673insC are likely to represent deleterious variants. In agreement with the functional analysis, the results of the computational analysis also indicated that the latter three variants are likely to be deleterious. Taken together, a combined approach of functional and bioinformatics analysis, plus structural modeling, can be utilized to obtain valuable information pertaining to the effect of a rare variant on the structure and function of BRCA1. Such information can, in turn, aid in the classification of BRCA1 variants for which there is a lack of genetic information needed to provide reliable risk assessment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18992264      PMCID: PMC2682550          DOI: 10.1016/j.mrfmmm.2008.09.017

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  55 in total

1.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.

Authors:  Georgia Chenevix-Trench; Sue Healey; Sunil Lakhani; Paul Waring; Margaret Cummings; Ross Brinkworth; Amie M Deffenbaugh; Lynn Anne Burbidge; Dmitry Pruss; Thad Judkins; Tom Scholl; Anna Bekessy; Anna Marsh; Paul Lovelock; Ming Wong; Andrea Tesoriero; Helene Renard; Melissa Southey; John L Hopper; Koulis Yannoukakos; Melissa Brown; Douglas Easton; Sean V Tavtigian; David Goldgar; Amanda B Spurdle
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

2.  Common BRCA1 variants and transcriptional activation.

Authors:  A N Monteiro; A August; H Hanafusa
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

3.  Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.

Authors:  J Vallon-Christersson; C Cayanan; K Haraldsson; N Loman; J T Bergthorsson; K Brøndum-Nielsen; A M Gerdes; P Møller; U Kristoffersson; H Olsson; A Borg; A N Monteiro
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

4.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

5.  Correlation of two-hybrid affinity data with in vitro measurements.

Authors:  J Estojak; R Brent; E A Golemis
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

6.  Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.

Authors:  R Scott Williams; J N Mark Glover
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

7.  Classification of BRCA1 missense variants of unknown clinical significance.

Authors:  C M Phelan; V Dapic; B Tice; R Favis; E Kwan; F Barany; S Manoukian; P Radice; R B van der Luijt; B P M van Nesselrooij; G Chenevix-Trench; T Caldes; M de la Hoya; S Lindquist; S V Tavtigian; D Goldgar; A Borg; S A Narod; A N A Monteiro
Journal:  J Med Genet       Date:  2005-02       Impact factor: 6.318

8.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

9.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

Review 10.  Inherited breast and ovarian cancer.

Authors:  C I Szabo; M C King
Journal:  Hum Mol Genet       Date:  1995       Impact factor: 6.150

View more
  14 in total

1.  Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.

Authors:  Tereza Vaclová; Nicholas T Woods; Diego Megías; Sergio Gomez-Lopez; Fernando Setién; José María García Bueno; José Antonio Macías; Alicia Barroso; Miguel Urioste; Manel Esteller; Alvaro N A Monteiro; Javier Benítez; Ana Osorio
Journal:  Hum Mol Genet       Date:  2016-12-15       Impact factor: 6.150

2.  A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1.

Authors:  Edwin S Iversen; Fergus J Couch; David E Goldgar; Sean V Tavtigian; Alvaro N A Monteiro
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-03-29       Impact factor: 4.254

3.  BaxΔ2 Family Alternative Splicing Salvages Bax Microsatellite-Frameshift Mutations.

Authors:  Bonnie Haferkamp; Honghong Zhang; Samuel Kissinger; Xin Wang; Yuting Lin; Megan Schultz; Jialing Xiang
Journal:  Genes Cancer       Date:  2013-11

4.  Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions.

Authors:  Kathleen A Clark; Andrew Paquette; Kayoko Tao; Russell Bell; Julie L Boyle; Judith Rosenthal; Angela K Snow; Alex W Stark; Bryony A Thompson; Joshua Unger; Jason Gertz; Katherine E Varley; Kenneth M Boucher; David E Goldgar; William D Foulkes; Alun Thomas; Sean V Tavtigian
Journal:  Am J Hum Genet       Date:  2022-06-02       Impact factor: 11.043

5.  BRCA1 Circos: a visualisation resource for functional analysis of missense variants.

Authors:  Ankita Jhuraney; Aneliya Velkova; Randall C Johnson; Bailey Kessing; Renato S Carvalho; Phillip Whiley; Amanda B Spurdle; Maaike P G Vreeswijk; Sandrine M Caputo; Gael A Millot; Ana Vega; Nicolas Coquelle; Alvaro Galli; Diana Eccles; Marinus J Blok; Tuya Pal; Rob B van der Luijt; Marta Santamariña Pena; Susan L Neuhausen; Talia Donenberg; Eva Machackova; Simon Thomas; Maxime Vallée; Fergus J Couch; Sean V Tavtigian; J N Mark Glover; Marcelo A Carvalho; Lawrence C Brody; Shyam K Sharan; Alvaro N Monteiro
Journal:  J Med Genet       Date:  2015-02-02       Impact factor: 6.318

6.  Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing.

Authors:  Anna Ruiz; Gemma Llort; Carmen Yagüe; Neus Baena; Marina Viñas; Montse Torra; Anna Brunet; Miquel A Seguí; Eugeni Saigí; Miriam Guitart
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

7.  Computational Analysis Reveals the Association of Threonine 118 Methionine Mutation in PMP22 Resulting in CMT-1A.

Authors:  Chundi Vinay Kumar; Rayapadi G Swetha; Anand Anbarasu; Sudha Ramaiah
Journal:  Adv Bioinformatics       Date:  2014-10-20

8.  Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance.

Authors:  Nicholas T Woods; Rebekah Baskin; Volha Golubeva; Ankita Jhuraney; Giuliana De-Gregoriis; Tereza Vaclova; David E Goldgar; Fergus J Couch; Marcelo Alex Carvalho; Edwin S Iversen; Alvaro Na Monteiro
Journal:  NPJ Genom Med       Date:  2016-03-02       Impact factor: 8.617

9.  Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.

Authors:  Alexandra V Stavropoulou; Florentia Fostira; Maroulio Pertesi; Marianthi Tsitlaidou; Gerassimos E Voutsinas; Olga Triantafyllidou; Aristotelis Bamias; Meletios A Dimopoulos; Eleni Timotheadou; Dimitrios Pectasides; Christos Christodoulou; George Klouvas; Christos Papadimitriou; Thomas Makatsoris; George Pentheroudakis; Gerasimos Aravantinos; Vassilis Karydakis; Drakoulis Yannoukakos; George Fountzilas; Irene Konstantopoulou
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

10.  In silico screening and molecular dynamics simulation of disease-associated nsSNP in TYRP1 gene and its structural consequences in OCA3.

Authors:  Balu Kamaraj; Rituraj Purohit
Journal:  Biomed Res Int       Date:  2013-06-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.